Preview Mode Links will not work in preview mode

May 31, 2022

A clinical investigator think tank and enduring multimedia activity with Drs Naval Daver, Stephen Strickland, Geoffrey Uy and Eunice Wang, including the following topics:

  • Introduction to therapy-related Acute Myeloid Leukemia (AML) (0:00)
  • Treatment of AML evolving from prior MDS (12:27)
  • Treatment of secondary AML in a patient ineligible for intensive therapy (29:41)
  • Treatment for a patient with secondary AML with an IDH mutation (40:56)
  • Long-term follow-up of CPX- 351 in patients with secondary AML (46:27)
  • Potential role of venetoclax in combination with intensive chemotherapy regimens (52:54)
  • Treatment for younger patients with secondary AML (58:46)
  • Treatment of secondary AML with a FLT3 mutation (1:03:59)
  • Data with CPX-351 in combination with targeted agents (1:08:30)
  • Refractory disease versus differentiation syndrome from IDH inhibitors (1:19:20)
  • Emerging data with menin inhibitors (1:28:13)
  • Treatment of secondary AML evolving from prior MPN (1:31:52)
  • Treatment of secondary AML with core binding factor (1:53:14)

CME information and select publications